No products in the cart.
Pre-made Fibatuzumab benchmark antibody ( Whole mAb, anti-EPHA3 therapeutic antibody, Anti-EK4/ETK/ETK1/HEK/HEK4/TYRO4 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-211
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Fibatuzumab biosimilar, Whole mAb, Anti-EPHA3 Antibody: Anti-EK4/ETK/ETK1/HEK/HEK4/TYRO4 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Fibatuzumab is a humanised monoclonal antibody directed against the ephrin receptor A3 (EPHA3) , which is a receptor tyrosine kinase implicated in mediating nervous system development .
| Products Name (INN Index) | Pre-Made Fibatuzumab biosimilar, Whole mAb, Anti-EPHA3 Antibody: Anti-EK4/ETK/ETK1/HEK/HEK4/TYRO4 therapeutic antibody |
|---|---|
| INN Name | Fibatuzumab |
| Target | EPHA3 |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2015 |
| Year Recommended | 2017 |
| Companies | Ludwig Institute for Cancer Research,Humanigen,Olivia Newton-John Cancer Research Institute |
| Conditions Approved | NA |
| Conditions Active | Acute myeloid leukaemia,Myelodysplastic syndromes,Myelofibrosis,Glioblastoma |
| Conditions Discontinued | NA |
| Development Tech | POTELLIGENT Technology;Humaneering Technology |
| Previous Name | ifabotuzumab |
| Gm Offical Target Name | EPHA3 |
| Package |
Previous slide
Next slide
